Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1985 1
1987 1
1988 3
1989 2
1990 4
1991 2
1992 3
1993 3
1994 4
1995 2
1996 1
1997 1
1998 3
1999 1
2000 1
2002 1
2003 1
2008 1
2009 3
2012 1
2014 1
2015 4
2016 2
2018 1
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Curtin F, Champion B, Davoren P, Duke S, Ekinci EI, Gilfillan C, Morbey C, Nathow T, O'Moore-Sullivan T, O'Neal D, Roberts A, Stranks S, Stuckey B, Vora P, Malpass S, Lloyd D, Maëstracci-Beard N, Buffet B, Kornmann G, Bernard C, Porchet H, Simpson R. Curtin F, et al. Among authors: porchet h. Diabetes Obes Metab. 2020 Jul;22(7):1111-1121. doi: 10.1111/dom.14010. Epub 2020 Mar 12. Diabetes Obes Metab. 2020. PMID: 32077207 Clinical Trial.
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Khan H, et al. Among authors: porchet h. Heart Fail Rev. 2009 Dec;14(4):277-87. doi: 10.1007/s10741-009-9136-z. Epub 2009 Feb 24. Heart Fail Rev. 2009. PMID: 19238540 Review.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. Derfuss T, et al. Among authors: porchet h. J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20. J Neuroimmunol. 2015. PMID: 26198921 Clinical Trial.
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP. Curtin F, et al. Among authors: porchet h. Mult Scler Relat Disord. 2016 Sep;9:95-100. doi: 10.1016/j.msard.2016.07.002. Epub 2016 Jul 1. Mult Scler Relat Disord. 2016. PMID: 27645352 Clinical Trial.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. Derfuss T, et al. Among authors: porchet h. Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12. Mult Scler. 2015. PMID: 25392325 Clinical Trial.
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page